STUDI PENGGUNAAN CALCIUM CHANNEL BLOCKER (CCB) PADA PASIEN STROKE HEMORRAGHIC
DOI:
https://doi.org/10.12928/mf.v10i2.1174Keywords:
Hemorrhagic Stroke, Calcium Channel Blocker (CCB), HospitalizationAbstract
Stroke adalah penyakit yang dapat menyebabkan kematian di dunia. Di Indonesia, dapat menyebabkan stroke yaitu hipertensi sehingga diperlukan antihipertensi, Metode penelitian yang dilakukan yaitu studi observasi dengan menggunakan sampel menunjukkan penggunaan CCB yaitu nicardipine 64%, nimodipine 12%, amlodipine 2%, dan diltiazem 6%. salah satunya adalah golongan Calcium Channel Blocker (CCB). Maksud penelitian ini yaitu meneliti penggunaan CCB pada pasien dengan hemorrhagicstroke hospitalizations di Rumah Sakit Umum (RSU) Dr. Saiful Anwar Malang.
retrospective descriptive method. Analisis dilakukan pada Bulan Januari sampai Desember 2012 pada medical records pasien yang didiagnosa menderita stroke
hemorrhagic dan menerima pengobatan CCB. Hasil dan Kesimpulan dari 54 jumlah pasien yang menderita stroke mencapai 8,3%. Faktor resiko terbesar yang
Downloads
Published
2013-09-30
Issue
Section
Pharmaceutical & Technology
License
Authors who publish with Media Farmasi agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution 4.0 International License